These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 32802982)

  • 1. Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz.
    Jordaan MA; Ebenezer O; Damoyi N; Shapi M
    Heliyon; 2020 Aug; 6(8):e04642. PubMed ID: 32802982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational investigation of potential inhibitors of novel coronavirus 2019 through structure-based virtual screening, molecular dynamics and density functional theory studies.
    Mishra SS; Ranjan S; Sharma CS; Singh HP; Kalra S; Kumar N
    J Biomol Struct Dyn; 2021 Aug; 39(12):4449-4461. PubMed ID: 32666910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer-aided identification of lead compounds as Staphylococcal epidermidis FtsZ inhibitors using molecular docking, virtual screening, DFT analysis, and molecular dynamic simulation.
    Tripathy S; Sahu SK; Azam MA; Jupudi S
    J Mol Model; 2019 Nov; 25(12):360. PubMed ID: 31773394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.
    Abdusalam AAA; Murugaiyah V
    Front Mol Biosci; 2020; 7():603037. PubMed ID: 33392261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based drug designing of naphthalene based SARS-CoV PLpro inhibitors for the treatment of COVID-19.
    Bhati S
    Heliyon; 2020 Nov; 6(11):e05558. PubMed ID: 33251371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic.
    Muteeb G; Alshoaibi A; Aatif M; Rehman MT; Qayyum MZ
    Appl Biol Chem; 2020; 63(1):79. PubMed ID: 33251389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of anti-filarial leads against aspartate semialdehyde dehydrogenase of Wolbachia endosymbiont of Brugia malayi: combined molecular docking and molecular dynamics approaches.
    Amala M; Rajamanikandan S; Prabhu D; Surekha K; Jeyakanthan J
    J Biomol Struct Dyn; 2019 Feb; 37(2):394-410. PubMed ID: 29334340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
    Kalhotra P; Chittepu VCSR; Osorio-Revilla G; Gallardo-Velazquez T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33578831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of Methyl-5-(pentan-3-yloxy)-7-oxabicyclo[4.1.0]hept-3-ene-3-carboxyhydrazide Derivatives as Potential Inhibitors of COVID-19 Main Protease: DFT and Molecular Docking Study.
    Akinyele OF; Fakola EG; Adeboye OO; Chinuomah SC
    Bioinform Biol Insights; 2023; 17():11779322231182050. PubMed ID: 37377795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore Identification, Molecular Docking, Virtual Screening, and In Silico ADME Studies of Non-Nucleoside Reverse Transcriptase Inhibitors.
    Pirhadi S; Ghasemi JB
    Mol Inform; 2012 Dec; 31(11-12):856-66. PubMed ID: 27476739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
    Maurya SK; Maurya AK; Mishra N; Siddique HR
    J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of Some Antiviral
    Hagar M; Ahmed HA; Aljohani G; Alhaddad OA
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Chemistry: Prediction of Compound Accessibility of Targeted Synthesized Compounds.
    Babu V; Ahmed S; Rahiman AK; Kawsar SMA; Berredjem M; Bhat AR; Basha KA
    Med Chem; 2024 Apr; ():. PubMed ID: 38638049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligand similarity guided receptor selection enhances docking accuracy and recall for non-nucleoside HIV reverse transcriptase inhibitors.
    Stanton RA; Nettles JH; Schinazi RF
    J Mol Model; 2015 Nov; 21(11):282. PubMed ID: 26450349
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Umar AB; Uzairu A
    J Taibah Univ Med Sci; 2023 Oct; 18(5):933-946. PubMed ID: 36875340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
    Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
    J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.